Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dorra Abdelmalek Driss

University of Sfax, Tunisia

Title: Density functional theory and molecular dynamics simulation support newly designed reversible tyrosine kinase inhibitors targeting double mutant Epidermal Growth Factor Receptor (EGFR)

Biography

Biography: Dorra Abdelmalek Driss

Abstract

Non-Small Cell Lung Cancer (NSCLC) is a leading cause of death in the world. Epidermal Growth Factor Receptor (EGFR) is a well-characterized oncogene that was shown to be implicated in the development of NSCLC via the acquisition of the L858R activating substitution. In this work, we aimed to identify novel reversible double mutant EGFR TKIs via an in silico approach. First, a compound library containing more than 150000 kinase inhibitor analogs was subjected to an initial filtering step. The remaining molecules were tested via high-throughput virtual screening that was carried out to identify the best inhibitors. Following this, a total of 15 hits were retained and their binding interactions and ADMET properties were determined. Finally, molecular dynamic studies were performed for the top 10 scoring compounds. Simulation analysis revealed that both molecules possessed interesting characteristics in terms of RMSD, RMSF, radius of gyration and hydrogen bonds formation. Of note, this study evaluated and established a library of compounds, top ranked virtual hit compounds binding reversibly to the double mutant EGFR enzyme can act as potent newly designed EGFR inhibitors in management of mutations of non-small cell lung cancer.